Author

M. Fujisawa

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 1 Microbiology· 1 Pathology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:cell type annotation· 2 Organism:human· 2 Organism:E. coli· 1 Research Focus:host-pathogen & immune response· 1 Assay:imaging· 1

Frequent Co-Authors

A. Matsukawa· 1 shared E. Kussell· 1 shared F. Shimizu· 1 shared H. Nakaoka· 1 shared H. Tomizawa-Shinohara· 1 shared J. Nemoto· 1 shared K. Matsuo· 1 shared K. Serizawa· 1 shared

Activity by Year

2021-2021 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 14 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperPathology

A. Matsukawa

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Observation of persister cell histories reveals diverse modes of survival in antibiotic persistence

M. Umetani, M. Fujisawa, R. Okura, T. Nozoe, S. Suenaga, H. Nakaoka, E. Kussell, Y. Wakamoto

The paper characterizes persister cell dynamics in E. coli by tracking individual cells exposed to antibiotics, revealing diverse survival mechanisms depending on growth phase and antibiotic type.

bioRxiv · Oct 28, 2021Microbiology

Expression of Spred2 in the urothelial tumorigenesis of the urinary bladder

S. Oda, M. Fujisawa, L. Chunning, T. Ito, T. Yamaguchi, T. Yoshimura, A. Matsukawa

The paper investigates Spred2 expression in urothelial tumors and finds it negatively correlates with ERK activation and Ki67 index in non-invasive papillary carcinoma.

bioRxiv · Jul 23, 2021Pathology

IL-6 blockade suppresses the blood-brain barrier disorder, leading to prevention of onset of NMOSD

Y. Takeshita, S. Fujikawa, K. Serizawa, M. Fujisawa, K. Matsuo, J. Nemoto, F. Shimizu, Y. Sano, H. Tomizawa-Shinohara, S. Miyake, R. M. Ransohoff, T. Kanda

The paper shows that IL-6 blockade with satralizumab prevents BBB disruption and lymphocyte migration induced by NMO-IgG in EAE and in vitro BBB models.

bioRxiv · Jan 28, 2021 · PreprintImmunology